Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1D22A antisense RNA 1 (TBC1D22A-AS1) is a human long non-coding RNA (lncRNA) gene classified as an antisense RNA relative to the protein-coding gene TBC1 domain family member 22A (TBC1D22A)[4][6][9][13]. The transcript is identified as a non-protein-coding RNA and is primarily annotated by genome databases for its genomic location and antisense orientation[4][6][13]. At present, there are no established biological functions, disease associations, or evidence that it serves as a therapeutic target[6][5][13]. There are also no approved drugs, mechanisms of drug action, or clinical biomarker roles for TBC1D22A-AS1, and it is not a member of any known major protein-based molecular family. It is typically included in transcriptomic datasets describing lncRNAs but does not currently have ascribed biomedical significance beyond its annotation as a putative
Not applicable (no drugs target this gene)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1D22A antisense RNA 1 (TBC1D22A-AS1).